[go: up one dir, main page]

IL128062A0 - Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same - Google Patents

Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL128062A0
IL128062A0 IL12806297A IL12806297A IL128062A0 IL 128062 A0 IL128062 A0 IL 128062A0 IL 12806297 A IL12806297 A IL 12806297A IL 12806297 A IL12806297 A IL 12806297A IL 128062 A0 IL128062 A0 IL 128062A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
pyrimidine derivatives
same
bicyclic pyrimidine
Prior art date
Application number
IL12806297A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL128062A0 publication Critical patent/IL128062A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL12806297A 1996-08-16 1997-08-14 Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same IL128062A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/699,372 US5693641A (en) 1996-08-16 1996-08-16 Bicyclic pyrimidine derivatives and their use as anti-coagulants
PCT/EP1997/004444 WO1998007723A1 (en) 1996-08-16 1997-08-14 Bicyclic pyrimidine derivatives and their use as anti-coagulants

Publications (1)

Publication Number Publication Date
IL128062A0 true IL128062A0 (en) 1999-11-30

Family

ID=24809035

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12806297A IL128062A0 (en) 1996-08-16 1997-08-14 Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same

Country Status (21)

Country Link
US (3) US5693641A (xx)
EP (1) EP0922045B1 (xx)
JP (1) JP2000516241A (xx)
KR (1) KR20000068173A (xx)
CN (1) CN1112363C (xx)
AT (1) ATE237617T1 (xx)
AU (1) AU724413B2 (xx)
CA (1) CA2261908A1 (xx)
CZ (1) CZ297323B6 (xx)
DE (1) DE69721008T2 (xx)
DK (1) DK0922045T3 (xx)
ES (1) ES2195163T3 (xx)
IL (1) IL128062A0 (xx)
NO (1) NO990708L (xx)
NZ (1) NZ333774A (xx)
PL (1) PL331634A1 (xx)
PT (1) PT922045E (xx)
RU (1) RU2198884C2 (xx)
SK (1) SK19199A3 (xx)
UA (1) UA59370C2 (xx)
WO (1) WO1998007723A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707323B2 (en) 1995-03-10 1999-07-08 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US5994375A (en) * 1996-02-12 1999-11-30 Berlex Laboratories, Inc. Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
DE69717474T2 (de) 1996-09-12 2003-06-26 Schering Ag Durch cyclische aminosäuren oder cyclische hydroxysäuren substituierte benzamidinderivate und deren verwendung als antikoagulantien
US6004985A (en) * 1996-10-09 1999-12-21 Berlex Laboratories, Inc. Thio acid derived monocylic N-heterocyclics as anticoagulants
US6686364B2 (en) 1997-12-08 2004-02-03 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
AU751856B2 (en) 1997-12-19 2002-08-29 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
US6262088B1 (en) 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6127376A (en) * 1998-12-04 2000-10-03 Berlex Laboratories, Inc. Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
US6350761B1 (en) 1999-07-30 2002-02-26 Berlex Laboratories, Inc. Benzenamine derivatives as anti-coagulants
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DE10239821A1 (de) * 2002-08-29 2004-03-11 Roche Diagnostics Gmbh Verbesserung der Spezifität bei der Bestimmung von Antithrombin
US7479502B2 (en) 2002-12-03 2009-01-20 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CA2666618C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
WO2010057118A2 (en) * 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
TWI557117B (zh) * 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
WO2011031965A1 (en) * 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
WO2014182822A1 (en) 2013-05-07 2014-11-13 St. Jude Medical, Atrial Fibrillation Division, Inc. Utilization of electrode spatial arrangements for characterizing cardiac conduction conditions
RU2016105108A (ru) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
MX2016009976A (es) 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Derivados de diazepam y sus usos.
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2940472A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
TW202412806A (zh) 2014-07-11 2024-04-01 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP2017525759A (ja) * 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
NZ729526A (en) 2014-09-16 2018-05-25 Gilead Sciences Inc Methods of preparing toll-like receptor modulators
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
JP7385356B2 (ja) 2015-11-25 2023-11-22 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド 二価ブロモドメインインヒビターおよびそれらの使用
HRP20241602T1 (hr) 2019-07-01 2025-01-31 Tonix Pharma Limited Antitijela anti-cd154 i njihova uporaba
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1297100C (en) * 1986-08-28 1992-03-10 Ryuji Niwa Medicament for curing arteriosclerosis, comprising pyrimido [2,1-b]-benxothiazole derivative
ES2190428T3 (es) * 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
WO1993015756A1 (en) * 1992-02-14 1993-08-19 Corvas International, Inc. Inhibitors of thrombosis
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
CA2151044A1 (en) * 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
US5332822A (en) * 1992-12-24 1994-07-26 Bristol-Myers Squibb Company Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors
ATE181334T1 (de) * 1993-02-12 1999-07-15 Corvas Int Inc Inhibitoren gegen thrombose
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives

Also Published As

Publication number Publication date
EP0922045A1 (en) 1999-06-16
PT922045E (pt) 2003-07-31
AU4015697A (en) 1998-03-06
CN1227553A (zh) 1999-09-01
US5846970A (en) 1998-12-08
JP2000516241A (ja) 2000-12-05
ATE237617T1 (de) 2003-05-15
PL331634A1 (en) 1999-08-02
DE69721008T2 (de) 2003-12-24
RU2198884C2 (ru) 2003-02-20
NO990708L (no) 1999-04-15
NZ333774A (en) 2000-08-25
NO990708D0 (no) 1999-02-15
CZ297323B6 (cs) 2006-11-15
US5846972A (en) 1998-12-08
US5693641A (en) 1997-12-02
UA59370C2 (uk) 2003-09-15
CN1112363C (zh) 2003-06-25
KR20000068173A (ko) 2000-11-25
EP0922045B1 (en) 2003-04-16
CZ50199A3 (cs) 1999-06-16
SK19199A3 (en) 1999-07-12
WO1998007723A1 (en) 1998-02-26
ES2195163T3 (es) 2003-12-01
AU724413B2 (en) 2000-09-21
DK0922045T3 (da) 2003-06-30
DE69721008D1 (de) 2003-05-22
HK1020058A1 (en) 2000-03-10
CA2261908A1 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
IL128062A0 (en) Bicyclic pyrimidine derivatives and pharmaceutical compositions containing the same
DE69732490D1 (en) Monozyclische n-heterozyclische thiosäure derivate als antikoagulans
IL128691A0 (en) Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL125285A0 (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and pharmaceutical compositions containing the same
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
EP1126849A4 (en) HETEROCYCLIC POTASSIAL CHANNEL INHIBITORS
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU2443184A (en) Benzazocinones and benzazoninones
EP1143965A4 (en) CARBOCYCLIC INHIBITORS OF POTASSIUM CHANNELS
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)